natgillin/translations-raw huggingface dataset:
After reconst. immediate use recommended.
Preporučuje se odmah upotrijebiti nakon pripreme otopine.
After reconstitution
Nakonrekonstitucije
After reconstitution (addition of 5 ml water for injections to the vial to dissolve the powder), 1 ml contains 50 mg bivalirudin.
Nakon pripreme otopine (dodavanje 5 ml vode za injekcije bočici kako bi se otopio prašak), 1ml sadrži 50 mg bivalirudina.
After reconstitution (see package leaflet), each vial contains 25 mg/ml of pemetrexed.
Nakon pripreme (vidjeti Uputu o lijeku), jedna bočica sadrži 25 mg/ml pemetrekseda.
After reconstitution 1 ml concentrate contains 1 mg topotecan.
Nakon pripreme, 1 ml koncentrata sadrži 1 mg topotekana.
After reconstitution 1 ml concentrate contains 1 mg topotecan.
Nakon rekonstitucije, 1 ml koncentrata sadrži 1 mg topotekana.
After reconstitution 1 ml concentrate contains 21 mg of trastuzumab
Nakon pripreme 1 ml koncentrata sadrži 21 mg trastuzumaba.
After reconstitution 1 ml contains 10 mg of sildenafil (as citrate).
Nakon pripreme, 1 ml sadrži 10 mg sildenafila (u obliku sildenafilcitrata).
After reconstitution 1 ml of the reconstituted solution contains 20 mg degarelix.
Nakon rekonstitucije 1 ml rekonstituirane otopine sadrži 20 mg degareliksa.
After reconstitution 1 ml of the reconstituted solution contains 40 mg degarelix.
Nakon rekonstitucije 1 ml rekonstituirane otopine sadrži 40 mg degareliksa.
After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml) (see section 6.6).
Nakon pripreme i razrjeđivanja, 1 ml otopine sadrži 1 mg fosaprepitanta (1 mg/ml) (vidjeti dio 6.6).
After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml).
Nakon pripreme i razrjeđenja otopine, 1 ml otopine sadrži 1 mg fosaprepitanta (1 mg/ml).
After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml).
Nakon pripreme i razrjeđivanja, 1 ml otopine sadrži 1 mg fosaprepitanta (1 mg/ml).
After reconstitution and dilution of the solution for intravenous infusion, this medicine contains between 0.6-6 mmol sodium per dose depending on the infusion fluid for dilution.
Nakon rekonstrukcije i razrjeđivanja otopine za intravensku infuziju, lijek sadrži između 0,6-6 mmola natrija po dozi, ovisno o vrsti infuzijske otopine za razrjeđivanje.
After reconstitution and dilution of the solution for intravenous infusion, this medicine contains between 1-10 mmol potassium per dose depending on the infusion fluid for dilution.
Nakon rekonstitucije i razrjeđivanja otopine za intravensku infuziju, lijek sadrži između 1-10 mmola kalija po dozi, ovisno o vrsti infuzijske otopine za razrjeđivanje.
After reconstitution and dilution, chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.
Nakon pripreme i razrjeđivanja, dokazana kemijsko fizikalna stabilnost lijeka u primjeni iznosi 24 sata pri 25°C.
After reconstitution and dilution, the solution should be administered by intravenous infusion over approximately 1 hour.
Nakon rekonstitucije i razrjeđivanja, otopinu treba primijeniti intravenskom infuzijom u trajanju od približno 1 sat.
After reconstitution and dilution: 24 hours at 25°C.
Nakon pripreme i razrjeđivanja: 24 sata na 25°C.
After reconstitution and infusion:
Pripremljena otopina i otopina za infuziju
After reconstitution and the first use the cartridge should remain in the pen and has to be kept in a refrigerator (2°C - 8°C) for a maximum of 21 days.
Nakon pripreme i prve primjene, uložak mora ostati u brizgalici te se mora čuvati u hladnjaku (2 °C - 8 °C) najdulje 21 dan.
After reconstitution each mL contains 10 mg infliximab.
Nakon pripreme otopine, 1 ml sadrži 10 mg infliksimaba.
After reconstitution each mL contains 10 mg infliximab.
Nakon rekonstitucije jedan ml sadrži 10 mg infliksimaba.
After reconstitution each ml contains 10 mg of infliximab.
Nakon pripreme otopine, 1 ml sadrži 10 mg infliksimaba.
After reconstitution each ml contains 10 mg of micafungin (as sodium).
Nakon rekonstitucije jedan ml sadrži 10 mg mikafungina (u obliku mikafunginnatrija).
After reconstitution each ml contains 10 mg of voriconazole.
Nakon pripreme, jedan ml sadrži 10 mg vorikonazola.
After reconstitution each ml contains 2,500 units of asparaginase.
Nakon rekonstitucije jedan ml sadrži 2500 jedinica asparaginaze.
After reconstitution each ml contains 20 mg dalbavancin.
Nakon rekonstitucije svaki ml sadrži 20 mg dalbavancina.
After reconstitution each ml contains 20 mg dalbavancin.
Nakon rekonstitucije svaki ml sadrži 20 ml dalbavancina.
After reconstitution each ml contains 20 mg of micafungin (as sodium).
Nakon rekonstitucije jedan ml sadrži 20 mg mikafungina (u obliku mikafunginnatrija).
After reconstitution each mL contains 50 mg tedizolid phosphate.
Nakon rekonstitucije, jedan ml sadrži 50 mg tedizolidfosfata.
After reconstitution each ml contains 60 mg of vedolizumab.
Nakon rekonstitucije jedan ml sadrži 60 mg vedolizumaba.
After reconstitution each ml of the solution contains 5 mg olanzapine
Nakon rekonstitucije jedan ml otopine sadrži 5 mg olanzapina.
After reconstitution each ml of the suspension contains 10 mg of sildenafil (as citrate).
Nakon pripreme, jedan ml suspenzije sadrži 10 mg sildenafila (u obliku sildenafilcitrata).
After reconstitution each vial contains 25 mg/ml of pemetrexed.
Nakon pripreme, jedna bočica sadrži 25 mg/ml pemetrekseda.
After reconstitution immediate use is recommended.
Preporučuje se primijeniti odmah nakon pripreme otopine.
After reconstitution it is a clear, colourless liquid, free from foreign matter.
Nakon pripreme za primjenu lijek je bistra, bezbojna tekućina koja ne sadrži vidljive čestice.
After reconstitution it is a clear, colourless liquid, free from foreign matter.
Nakon pripreme za primjenu otopina je bistra, bezbojna i bez vidljivih čestica.
After reconstitution it is a clear, colourless liquid, free from foreign matter.
Nakon rekonstitucije,,otopina je bistra, bezbojna tekućina i ne sadrži vidljive čestice.
After reconstitution it is recommended to promptly dilute the vials (see below).
Nakon rekonstitucije preporučuje se odmah razrijediti sadržaj bočica (vidjeti u nastavku).
After reconstitution of the lyophilisate with the solvent, shake gently and administer five injections (each approximately 0.2 ml) around the tumour excision site: one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centred on the middle of the surgical scar.
Nakon rekonstitucije liofilizata s otapalom, lagano protresite te pet injekcija (svaku od oko 0,2 ml) primijenite oko mjesta ekscizije tumora: po jednu injekciju u svakom kutu i jednu injekciju u središtu kvadrata od 5 cm x 5 cm na sredini kirurškog ožiljka.
After reconstitution of the lyophilisate with the solvent, shake gently and administer immediately one dose of 1 ml subcutaneously according to the following vaccination schedule:
Nakon rekonstitucije liofilizata s otapalom blago protresti i odmah aplicirati jednu dozu od 1 ml potkožno prema sljedećem rasporedu cijepljenja:
After reconstitution one vial contains 125 mg/ml of omalizumab (150 mg in 1.2 ml).
Nakon pripreme otopine, jedna bočica sadrži 125 mg/ml omalizumaba (150 mg u 1,2 ml).
After reconstitution one vial contains 125 mg/ml of omalizumab (75 mg in 0.6 ml).
Nakon pripreme otopine, jedna bočica sadrži 125 mg/ml omalizumaba (75 mg u 0,6 ml).
After reconstitution the injection should be administered immediately.
Nakon rekonstitucije, injekcija se mora odmah primijeniti.
After reconstitution the liquid should be clear and colourless.
Nakon pripreme za primjenu, tekućina mora biti bistra i bezbojna.
After reconstitution the medicinal product should be used immediately before the suspension settles.
Nakon rekonstitucije, lijek treba primijeniti odmah, prije nego što se suspenzija slegne.
After reconstitution the solution is clear.
Otopina je nakon pripreme za primjenu bistra.
After reconstitution the solution is colourless to slightly yellowish and clear to slightly opalescent and essentially free from visible particles.
Nakon pripreme, otopina je bezbojna do blago žućkasta, bistra do blago opalescentna i u biti bez vidljivih čestica.
After reconstitution the solution should be clear and colourless to pale yellow.
Rekonstituirana otopina mora biti bistra i bezbojna do blijedožuta.
After reconstitution the solution should be clear, colourless and free from foreign particles.
Otopina nakon pripreme treba biti bistra, bezbojna i bez vidljivih čestica.
After reconstitution the solution should be clear, colourless and free from foreign particles.
Otopina nakon rekonstitucije treba biti bistra, bezbojna i bez vidljivih čestica.
After reconstitution this medicinal product contains 0.31 mmol sodium (7 mg) per ml of reconstituted solution.
Nakon rekonstitucije ovaj lijek sadrži 0,31 mmol natrija (7 mg) po ml rekonstituirane otopine.
After reconstitution this medicinal product contains 0.83 mmol (19 mg) sodium per vial.
Nakon rekonstitucije ovaj lijek sadrži 0,83 mmol (19 mg) natrija po bočici.
After reconstitution use within 3 hours.
Upotrijebiti unutar 3 sata od pripreme.
After reconstitution use within 4 hours.
Nakon rekonstitucije upotrijebiti unutar 4 sata.
After reconstitution use within 4 hours.
Upotrijebiti 4 sata nakon rekonstitucije.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 10 mg pegvisomant.
Nakon pripreme s 1 ml otapala, 1 ml otopine sadrži 10 mg pegvisomanta.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 15 mg pegvisomant.
Nakon pripreme s 1 ml otapala, 1 ml otopine sadrži 15 mg pegvisomanta.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 20 mg pegvisomant.
Nakon pripreme s 1 ml otapala, 1 ml otopine sadrži 20 mg pegvisomanta.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 25 mg pegvisomant.
Nakon pripreme s 1 ml otapala, 1 ml otopine sadrži 25 mg pegvisomanta.
After reconstitution with 1 ml of solvent, 1 ml of the solution contains 30 mg pegvisomant.
Nakon pripreme s 1 ml otapala, 1 ml otopine sadrži 30 mg pegvisomanta.
After reconstitution with 10 ml of water for injections, each ml of concentrate contains 5 mg of decitabine.
Nakon pripreme s 10 ml vode za injekcije, jedan ml koncentrata sadrži 5 mg decitabina.
After reconstitution with 10 ml the solution contains 100 IU/ml of FVIII and 240 IU/ml of VWF.
Nakon rekonstitucije s 10 ml, otopina sadrži 100 IU/ml FVIII i 240 IU/ml VWF.
After reconstitution with 10 ml the solution contains 50 IU/ml of FVIII and 120 IU/ml of VWF.
Nakon rekonstitucije s 10 ml, što odgovara koncentraciji od 50 IU/ml FVIII i 120 IU/ml VWF.
After reconstitution with 100 mL of diluent, each mL of the reconstituted solution contains 25 mg of hydroxocobalamin.
Nakon pripreme za primjenu sa 100 mL otapala jedan mL pripremljene otopine sadrži 25 mg hidroksokobalamina.
After reconstitution with 100 mL of diluent, each mL of the reconstituted solution contains 25 mg of hydroxocobalamin.
Nakon rekonstitucije sa 100 mL otapala, jedan mL pripremljene otopine sadrži 25 mg hidroksokobalamina.
After reconstitution with 14 ml water for injections, the solution contains 150 U conestat alfa per ml.
Nakon rekonstitucije s 14 ml vode za injekcije otopina sadrži 150 U konestata alfa po ml.
After reconstitution with 19 ml of water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection a clear solution is obtained.
Nakon pripreme s 19 ml vode za injekcije ili otopine natrijevog klorida za injekciju od 9 mg/ml (0,9%) dobiva se bistra otopina.
After reconstitution with 200 mL of diluent, each mL of the reconstituted solution contains 25 mg of hydroxocobalamin.
Nakon pripreme za primjenu sa 200 mL otapala jedan mL pripremljene otopine sadrži 25 mg hidroksokobalamina.
After reconstitution with 200 mL of diluent, each mL of the reconstituted solution contains 25 mg of hydroxocobalamin.
Nakon rekonstitucije s 200 mL otapala, jedan mL pripremljene otopine sadrži 25 mg hidroksokobalamina.
After reconstitution with 200 mL of diluent, each mL of the reconstituted solution contains 25 mg of hydroxocobalamin.
Nakon rekonstitucije sa 200 mL otapala, jedan mL pripremljene otopine sadrži 25 mg hidroksokobalamina.
After reconstitution with 25 ml Savene diluent, 1 ml of concentrate contains 20 mg dexrazoxane
Nakon pripreme s 25 ml otapala lijeka Savene, 1 ml koncentrata sadrži 20 mg deksrazoksana.
After reconstitution with 4 mL of water for injections, the reconstituted suspension contains 25 mg/mL azacitidine.
Nakon pripreme s 4 mL vode za injekcije, suspenzija sadrži 25 mg/mL azacitidina.
After reconstitution with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection, each ml of concentrate contains pixantrone dimaleate equivalent to 5.8 mg pixantrone.
Nakon rekonstitucije s 5 ml 0,9 %-tne otopine natrijevog klorida za injekcije (9 mg/ml) svaki ml koncentrata sadrži piksantrondimaleat koji odgovara 5,8 mg piksantrona.
After reconstitution with 5 ml the solution contains 100 IU/ml of FVIII and 240 IU/ml of VWF.
Nakon rekonstitucije s 5 ml, otopina sadrži 100 IU/ml FVIII i 240 IU/ml VWF.
After reconstitution with 5 ml the solution contains 50 IU/ml of FVIII and 120 IU/ml of VWF.
Nakon rekonstitucije s 5 ml, otopina sadrži 50 IU/ml FVIII i 120 IU/ml VWF.
After reconstitution with 52 ml of water, the usable volume of oral suspension allows for the retrieval of a total of 10 doses of 75 mg oseltamivir.
Nakon rekonstitucije s 52 ml vode, upotrebljiva količina oralne suspenzije omogućuje korištenje ukupno 10 doza od 75 mg oseltamivira.
After reconstitution with 7.2 ml water for injections, each vial of Fabrazyme contains 5 mg/ml (35 mg/7 ml) of agalsidase beta.
Nakon rekonstitucije sa 7,2 ml vode za injekcije jedna bočica lijeka Fabrazyme sadrži 5 mg/ml (35 mg/7 ml) agalzidaze beta.
After reconstitution with acceptable solvents, Dynastat may only be injected IV or IM, or into IV
Nakon rekonstitucije s prihvatljivim otapalima, Dynastat se smije injicirati samo i.v. ili i.m. ili u i.v. linije kojima se daju:
After reconstitution with acceptable solvents, Dynastat may only be injected IV or IM, or into IV lines delivering the following:
Nakon rekonstitucije s prihvatljivim otapalima, Dynastat se smije ubrizgati samo i.v. ili i.m. ili u i.v. linije kroz koje se primjenjuju sljedeće otopine:
After reconstitution with the solvent provided and the radiolabelling with sodium pertechnetate (99mTc) injection, the resulting clear and colourless solution for injection of technetium (99mTc)-besilesomab has a pH of 6.5-7.5.
Nakon rekonstitucije pomoću priloženog otapala i radioaktivnog obilježavanja pomoću injekcije natrijevog pertehnetata (99mTc), nastaje bistra, bezbojna otopina za injekciju tehnicijevog (99mTc) besilesomaba, čiji pH iznosi 6,5-7,5.
After reconstitution with the solvent provided, each ml of the solution contains 0.25 mg cetrorelix.
Nakon rekonstitucije s priloženim otapalom, jedan ml otopine sadrži 0,25 mg cetroreliksa.
After reconstitution with the supplied solvent (0.234% sodium chloride solution), each vial contains 50, 100, 200, 400 or 600 IU/ml (see Table 1).
Nakon pripreme s priloženim otapalom (0,234% otopina natrijevog klorida), jedna bočica sadrži 50, 100, 200, 400 ili 600 IU/ml (vidjeti tablicu 1).
After reconstitution with the supplied solvent [sodium chloride 9 mg/ml (0.9%) solution], each vial contains 62.5, 125, 250, or 500 IU, respectively (based on the strength of moroctocog alfa, i.e., 250, 500, 1000, or 2000 IU), of moroctocog alfa per 1 ml of the prepared solution for injection.
Nakon pripreme s priloženim otapalom [otopinom natrijevog klorida 9 mg/ml (0,9%)], jedna bočica sadrži 62,5, 125, 250 odnosno 500 IU (ovisno o jačini moroktokoga alfa, tj., 250, 500, 1000 ili 2000 IU) moroktokoga alfa po 1 ml pripremljene otopine za injekciju.
After reconstitution with the supplied solvent [sodium chloride 9 mg/ml (0.9%) solution], the prepared solution for injection contains either 62.5, 125, 250, 500 or 750 IU of moroctocog alfa per ml, respectively (based on the strength of moroctocog alfa, i.e., 250, 500, 1000, 2000, or 3000 IU).
Nakon pripreme s priloženim otapalom [otopinom natrijevog klorida 9 mg/ml (0,9%)], pripremljena otopina za injekciju sadrži 62,5, 125, 250, 500 odnosno 750 IU moroktokoga alfa po ml (na temelju jačine moroktokoga alfa, tj., 250, 500, 1000, 2000 ili 3000 IU).
After reconstitution with water for injections, the reconstituted solution, if not used immediately, should be protected from direct sunlight, and stored refrigerated at 2C - 8C.
Nakon rekonstitucije s vodom za injekcije, rekonstituiranu otopinu, ako se ne koristi odmah, treba zaštititi od izravne sunčeve svjetlosti te čuvati u hladnjaku na temperaturi 2C - 8C.
After reconstitution, 0.4 mL of suspension contains 4 mg somatropin (10 mg/mL).
Nakon rekonstitucije, 0,4 ml suspenzije sadrži 4 mg somatropina (10 mg/ml).
After reconstitution, 0.5 mL of suspension contains 10 mg somatropin (20 mg/mL).
Nakon rekonstitucije, 0,5 ml suspenzije sadrži 10 mg somatropina (20 mg/ml).
After reconstitution, 0.7 mL of suspension contains 7 mg somatropin (10 mg/mL).
Nakon rekonstitucije, 0,7 ml suspenzije sadrži 7 mg somatropina (10 mg/ml).
After reconstitution, 1 dose (0.5 ml) contains 5 micrograms of Neisseria meningitidis group A, C, W- 135 and Y polysaccharides.
Nakon rekonstitucije, 1 doza (0,5 ml) cjepiva sadrži 5 mikrograma polisaharida Neisseria meningitidis grupe A, C, W-135 i Y.
After reconstitution, 1 dose (0.5 ml) contains:
Nakon rekonstitucije, 1 doza (0,5 ml) cjepiva sadrži:
After reconstitution, 1 dose (0.5 ml) contains:
Nakon rekonstitucije, 1 doza (0,5 ml) sadržava:
After reconstitution, 1 dose (0.65 ml) contains:
Nakon pripreme, 1 doza (0,65 ml) sadrži:
After reconstitution, 1 dose (0.65 ml) contains: The active substance is:
Nakon pripreme, 1 doza (0,65 ml) sadrži: Djelatna tvar je:
After reconstitution, 1 dose (1 ml) contains:
Nakon rekonstitucije, 1 doza (1 ml) sadrži:
After reconstitution, 1 ml concentrate contains 1 mg topotecan.
Nakon pripreme, 1 ml koncentrata sadrži 1 mg topotekana.
After reconstitution, 1 ml contains 2 mg of verteporfin.
Nakon pripreme otopine za primjenu 1 ml sadrži 2 mg verteporfina.
After reconstitution, 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b*
Nakon pripreme otopine 1 ml sadrži 250 mikrograma (8,0 milijuna IU) interferona beta-1b
After reconstitution, 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b*
Nakon pripreme otopine 1 ml sadrži 250 mikrograma (8,0 milijuna IU) interferona beta-1b*.
After reconstitution, 1 mL of oral suspension contains 25 mg of aprepitant.
Nakon pripreme za primjenu, 1 ml oralne suspenzije sadrži 25 mg aprepitanta.
After reconstitution, 1 ml of solution contains 10 mg of pegvisomant.* Excipient with known effect
Nakon rekonstitucije, 1 ml otopine sadrži 10 mg pegvisomanta.* Pomoćna tvar s poznatim učinkom
After reconstitution, 1 ml of solution contains 10 mg pegvisomant
Nakon pripreme, 1 ml otopine sadrži 10 mg pegvisomanta
After reconstitution, 1 ml of solution contains 15 mg of pegvisomant.* Excipient with known effect
Nakon rekonstitucije, 1 ml otopine sadrži 15 mg pegvisomanta.* Pomoćna tvar s poznatim učinkom
After reconstitution, 1 ml of solution contains 15 mg pegvisomant
Nakon pripreme, 1 ml otopine sadrži 15 mg pegvisomanta
After reconstitution, 1 ml of solution contains 20 mg of pegvisomant.* Excipient with known effect:
Nakon rekonstitucije, 1 ml otopine sadrži 20 mg pegvisomanta.* Pomoćna tvar s poznatim učinkom
After reconstitution, 1 ml of solution contains 20 mg pegvisomant
Nakon pripreme, 1 ml otopine sadrži 20 mg pegvisomanta
After reconstitution, 1 ml of solution contains 25 mg of pegvisomant.* Excipient with known effect
Nakon rekonstitucije, 1 ml otopine sadrži 25 mg pegvisomanta.* Pomoćna tvar s poznatim učinkom
After reconstitution, 1 ml of solution contains 25 mg pegvisomant
Nakon pripreme, 1 ml otopine sadrži 25 mg pegvisomanta
After reconstitution, 1 ml of solution contains 30 mg of pegvisomant.* Excipient with known effect
Nakon rekonstitucije, 1 ml otopine sadrži 30 mg pegvisomanta.* Pomoćna tvar s poznatim učinkom
After reconstitution, 1 ml of solution contains 30 mg pegvisomant
Nakon pripreme, 1 ml otopine sadrži 30 mg pegvisomanta
After reconstitution, 1 ml of solution for infusion contains 2.5 mg temozolomide.
Nakon pripreme 1 ml otopine za infuziju sadrži 2,5 mg temozolomida.
After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib.
Nakon pripreme, 1 ml otopine za primjenu injekcijom u venu sadrži 1 mg bortezomiba.
After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib.
Nakon rekonstitucije, 1 ml otopine za primjenu injekcijom u venu sadrži 1 mg bortezomiba.
After reconstitution, 1 ml of solution for subcutaneous injection contains 2.5 mg bortezomib.
Nakon pripreme, 1 ml otopine za primjenu potkožnom injekcijom sadrži 2,5 mg bortezomiba.
After reconstitution, 1 ml of solution for subcutaneous injection contains 2.5 mg bortezomib.
Nakon rekonstitucije, 1 ml otopine za primjenu potkožnom injekcijom sadrži 2,5 mg bortezomiba.
After reconstitution, 1 mL of suspension contains 20 mg somatropin (20 mg/mL).
Nakon rekonstitucije, 1 ml suspenzije sadrži 20 mg somatropina (20 mg/ml).
After reconstitution, 1 ml of the solution contains 30 mg of ceftaroline fosamil.
Nakon rekonstitucije, 1 ml otopine sadrži 30 mg ceftarolinfosamila.
After reconstitution, 1 mL oral suspension contains 25 mg of aprepitant
Nakon pripreme za primjenu, 1 ml oralne suspenzije sadrži 25 mg aprepitanta.
After reconstitution, 1dose (0.5 ml) contains (live, attenuated):
Nakon pripreme, 1 doza (0,5 ml) sadrži (živi, atenuirani):
After reconstitution, 1dose (0.65 ml) contains:
Nakon pripreme, 1 doza (0,65 ml) sadrži:
After reconstitution, a deliverable volume of 0.5 ml solution contains 250 micrograms of romiplostim (500 micrograms/ml).
Nakon pripreme, korisni volumen od 0,5 ml otopine sadrži 250 mikrograma romiplostima (500 mikrograma/ml).
After reconstitution, a deliverable volume of 0.5 ml solution contains 250 micrograms of romiplostim (500 micrograms/ml).
Nakon pripreme, korisni volumen od 0,5 ml otopine, sadrži 250 mikrograma romiplostima (500 mikrograma/ml).
After reconstitution, a deliverable volume of 0.5 ml solution contains 250 µg of romiplostim (500 µg/ml).
Nakon rekonstitucije, korisni volume od 0,5 ml otopine sadrži 250 µg romiplostima (500 µg/ml).
After reconstitution, a deliverable volume of 0.5 ml solution contains 250 µg of romiplostim (500 µg/ml).
Nakon rekonstitucije, korisni volumen od 0,5 ml otopine sadrži 250 µg romiplostima (500 µg/ml).
After reconstitution, a deliverable volume of 1 ml solution contains 500 micrograms of romiplostim (500 micrograms/ml).
Nakon pripreme, korisni volumen od 1 ml otopine sadrži 500 mikrograma romiplostima (500 mikrograma/ml).
After reconstitution, a deliverable volume of 1 ml solution contains 500 micrograms of romiplostim (500 micrograms/ml).
Nakon pripreme, korisni volumen od 1 ml otopine, sadrži 500 mikrograma romiplostima (500 mikrograma/ml).
After reconstitution, a deliverable volume of 1 ml solution contains 500 µg of romiplostim (500 µg/ml).
Nakon rekonstitucije, korisni volume od 1 ml otopine sadrži 500 µg romiplostima (500 µg/ml).
After reconstitution, a deliverable volume of 1 ml solution contains 500 µg of romiplostim (500 µg/ml).
Nakon rekonstitucije, korisni volumen od 1 ml otopine sadrži 500 µg romiplostima (500 µg/ml).
After reconstitution, administer 1 dose of vaccine by coarse spray or by the oculonasal route of administration to chickens from 1 day of age or older.
Nakon rekonstitucije, primijenite 1 dozu cjepiva pomoću raspršivača ili okulo-nazalnim putem pilićima u dobi od 1 dana ili starijima.
After reconstitution, administer 1 dose of vaccine by subcutaneous injection to rabbits from 5 weeks of age onwards.
Nakon rekonstitucije 1 dozu cjepiva dati subkutano kunićima od 5 tjedana starosti nadalje.
After reconstitution, chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C or for 4 hours at room temperature.
Nakon rekonstitucije, kemijska i fizikalna stabilnost u primjeni iznosi 24 sata na 2oC - 8oC ili do 4 sata na sobnoj temperaturi.